Pharma Deals Review, Vol 2005, No 63 (2005)

Font Size:  Small  Medium  Large

Sereno and Genmab Partner Again with a US$215 M Deal

Business Review Editor

Abstract


Genmab granted Sereno the exclusive worldwide rights to develop and commercialize Genmab’s Phase III drug, Humax-CD4 (zanolimumab) used for treating cutaneous T-cell lymphoma. The total value of the deal is US$215 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.